Sjogren's syndrome
Not recruitingEfficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Disease:Sjogren's syndrome
- Substances:Dazodalibep
France- Participants:18–64 years · 65+ years
- Substances:Dazodalibep
- Sponsor:Horizon Therapeutics Ireland Designated Activity Company












